/
Oncology
Advanced/metastatic Solid Tumors
52
Pipeline Programs↗
44
Active Trials↗
37
Companies Involved↗
Advanced/Metastatic Solid Tumors is a moderately active landscape with 52 programs across 37 companies. The most active players are Shanghai Henlius Biotech, BioNTech, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 126
Phase 219
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
42 of 48 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 48 classified programs, each share of the total. Modality classified for 98% of 52 pipeline programs.
Analysis
Trial Status
70
clinical trials
Recruiting38 · 54%
Terminated10 · 14%
Completed10 · 14%
Unknown status6 · 9%
Not yet recruiting3 · 4%
Active, not recruiting3 · 4%
Clinical Trials
Trial Activity
70 trials
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)